The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Machine learning applications in drug development
Open accessAbstract
Due to the huge amount of biological and medical data available today, along with well-established machine learning algorithms, the design of largely automated drug development pipelines can now be envisioned. These pipelines may guide, or speed up, drug discovery; provide a better understanding of diseases and associated biological phenomena; help planning preclinical wet-lab experiments, and even future clinical trials. This automation of the drug development process might be key to the current issue of low productivity rate that pharmaceutical companies currently face. In this survey, we will particularly focus on two classes of methods: sequential learning and recommender systems, which are active biomedical fields of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
Gaussian Processes for Machine Learning
Rasmussen, C. E., & Williams, C. K. I. (2005) · doi:10.7551/mitpress/3206.001.0001 · Cited by 11,705
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
Applications of machine learning in drug discovery and development
Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0024-5 · Cited by 3,228
Deep learning for healthcare: review, opportunities and challenges
Miotto, R., Wang, F., Wang, S., Jiang, X., & Dudley, J. T. (2018) · Briefings in Bioinformatics · doi:10.1093/bib/bbx044 · Cited by 3,076 · cited 1×
“Automatic feature selection algorithms can take advantage of the great flexibility and learning power of Deep Neural Networks, that, provided the raw input data and the expected outcome, create the most discriminant features [116,117].”
BackgroundTHOMPSON, W. R. (1933) · Biometrika · doi:10.1093/biomet/25.3-4.285 · Cited by 2,712
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Research works printed but not linked: 87
- Eliopoulos H., Giranda V., Carr R., Tiehen R., Leahy T. and Gordon G.: Phase 0 trials: an industry perspective. Clin Cancer Res 2008; 14: 3683. · doi:10.1158/1078-0432.ccr-07-4586
- 10.7150/ijbs.24612 · DOI · Paper page
- Schuhmacher A., Gassmann O. and Hinder M.: Changing R&D models in research-based pharmaceutical companies. J Transl Med 2016; 14: 105. · DOI · Paper page
- Hwang T.J., Carpenter D., Lauffenburger J.C., Wang B., Franklin J.M. and Kesselheim A.S.: Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Med 2016; 176: 1826. · DOI · Paper page
- Pharmaprojects. Pharma r&d annual review 2018. Available at: pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/files/infographics/pharmaprojects-2018-pharma-rd-infographic.pdf. Accessed [September 16 2019].
- Meekings K.N., Williams C.S. and Arrowsmith J.E.: Orphan drug development: an economically viable strategy for biopharma R&D. Drug Discovery Today 2012; 17: 660. · DOI · Paper page
- Waterfield P. How Is Machine Learning Accelerating Drug Development? Available at: journal.binarydistrict.com/how-is-machine-learning-accelerating-drug-development. Accessed [September 16 2019].
- Chan H.S., Shan H., Dahoun T., Vogel H. and Yuan S.: Advancing drug discovery via artificial intelligence. Trends Pharmacol Sci 2019; .
- 10.1038/nrd.2017.226 · DOI · Paper page
- 10.1101/gr.3851306 · DOI
- Hodos R.A., Kidd B.A., Khader S., Readhead B.P. and Dudley J.T.: Computational approaches to drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 2016; 8: 186. · DOI · Paper page
- Musa A., Ghoraie L.S., Zhang S.D., Glazko G., Yli-Harja O., Dehmer M. et al: A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinf 2017; 19: 506.
- Srivastava P.K., van Eyll J., Godard P., Mazzuferi M., Delahaye-Duriez A., Van Steenwinckel J. et al: A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target. Nat Commun 2018; 9: 3561. · DOI
- 10.1021/acs.molpharmaceut.6b00248 · DOI · Paper page
- Schölkopf B., Tsuda K. and Vert J.P.: Support vector machine applications in computational biology. : MIT Press 2004.
- 10.1016/j.drudis.2018.01.039 · DOI · Paper page
- Lattimore T Szepesvári C. Bandit algorithms; 2018. preprint.
- Kaufmann E. and Garivier A.: Learning the distribution with largest mean: two bandit frameworks. ESAIM: Proceed Surveys 2017; 60: 114. · DOI
- Mary J Gaudel R Preux P. Bandits and recommender systems. In: International Workshop on Machine Learning Optimization and Big Data; 2015. Springer Cham. p. 325–36. · DOI
- Guillou F., Gaudel R. and Preux P.: Large-scale bandit recommender system.. In: International workshop on machine learning, optimization, and big data. Cham: Springer 2016: 204. · DOI
- Adomavicius G. and Tuzhilin A.: Toward the next generation of recommender systems: a survey of the state-of-the-art and possible extensions. IEEE Trans Knowl Data Eng 2005; 6: 734. · DOI · Paper page
- Brynjolfsson E Hu YJ Smith MD. The longer tail: The changing shape of Amazon’s sales distribution curve; 2010. Available at SSRN 1679991. · DOI
- Smith B. and Linden G.: Two decades of recommender systems at Amazon. com. IEEE Internet Comput 2017; 21: 12. · DOI · Paper page
- Li L Chu W Langford J Schapire RE. A contextual-bandit approach to personalized news article recommendation. In: Proceedings of the 19th international conference on world wide web; 2010 ACM. p. 661–70. · DOI · Paper page
- Rifaioglu AS Atas H Martin MJ Cetin-Atalay R Atalay V Dogan T. Recent applications of deep learning and machine intelligence on in silico drug discovery: methods tools and databases. Brief Bioinform; 2018 10. · DOI · Paper page
- Ferrero E., Dunham I. and Sanseau P.: In silico prediction of novel therapeutic targets using gene–disease association data. J Transl Med 2017; 15: 182. · DOI
- Celesti F Celesti A Carnevale L Galletta A Campo S Romano A et al. Big data analytics in genomics: The point on Deep Learning solutions. In: 2017 IEEE Symposium on Computers and Communications (ISCC); 2017. IEEE. p. 306–9. · DOI
- Riniker S., Wang Y., Jenkins J.L. and Landrum G.A.: Using information from historical high-throughput screens to predict active compounds. J Chem Inf Model 2014; 54: 1880. · DOI
- Zou J., Huss M., Abid A., Mohammadi P., Torkamani A. and Telenti A.: A primer on deep learning in genomics. Nat Genet 2018; 1.
- Goodfellow I Pouget-Abadie J Mirza M Xu B Warde-Farley D Ozair S et al. Generative adversarial nets. In: Advances in neural information processing systems; 2014. p. 2672–80.
- Killoran N Lee LJ Delong A Duvenaud D Frey BJ. Generating and designing DNA with deep generative models; 2017. arXiv preprint arXiv:1712.06148. · arXiv
- Gupta A Zou J. Feedback GAN (FBGAN) for DNA: A novel feedback-loop architecture for optimizing protein functions; 2018. arXiv preprint arXiv:1804.01694. · arXiv
- Kandasamy K Krishnamurthy A Schneider J Póczos B. Parallelised bayesian optimisation via Thompson sampling. In: International Conference on Artificial Intelligence and Statistics; 2018. p. 133–42.
- Griffiths RR Hernández-Lobato JM. Constrained bayesian optimization for automatic chemical design; 2017. arXiv preprint arXiv:1709.05501. · arXiv
- Anand N Huang P. Generative modeling for protein structures. In: Advances in neural information processing systems; 2018. p. 7494–7505.
- Gonzalez J Longworth J James DC Lawrence ND. Bayesian optimization for synthetic gene design; 2015. arXiv preprint arXiv:1505.01627. · arXiv
- Pyzer-Knapp E.O.: Bayesian optimization for accelerated drug discovery. IBM J Res Dev 2018; 62: 2.
- Benhenda M. ChemGAN challenge for drug discovery: can AI reproduce natural chemical diversity?; 2017. arXiv preprint arXiv:1708.08227. · DOI
- Grimm D. U.S. EPA to eliminate all mammal testing by 2035. Available at: sciencemag.org/news/2019/09/us-epa-eliminate-all-mammal-testing-2035. Accessed [September 13 2019]. · DOI
- Aziz M Kaufmann E Riviere MK. On Multi-Armed Bandit Designs for Phase I Clinical Trials; 2019. arXiv preprint arXiv:1903.07082. · arXiv
- Berry S.M., Carlin B.P., Lee J.J. and Muller P.: Bayesian adaptive methods for clinical trials. : CRC Press 2010. · DOI · Paper page
- Satlin A., Wang J., Logovinsky V., Berry S., Swanson C., Dhadda S. et al: Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimer’s Dementia: Transl Res Clin Intervent 2016; 2: 1.
- 10.1080/00031305.1987.10475458 · DOI
- Lai T.L. and Robbins H.: Asymptotically efficient adaptive allocation rules. Adv Appl Math 1985; 6: 4. · DOI · Paper page
- Berry D.A. and Fristedt B.: Bandit problems: sequential allocation of experiments (monographs on statistics and applied probability). London: Chapman and Hall 1985: 71. · DOI · Paper page
- Jennison C., Johnstone I.M. and Turnbull B.W.: Asymptotically optimal procedures for sequential adaptive selection of the best of several normal means. In: Statistical decision theory and related topics III. : Academic Press 1982: 55. · doi:10.1016/b978-0-12-307502-4.50010-6
- Bechhofer R.E.: A single-sample multiple decision procedure for ranking means of normal populations with known variances. Ann Math Stat 1954; : 16. · DOI · Paper page
- Even-Dar E., Mannor S. and Mansour Y.: Action elimination and stopping conditions for the multi-armed bandit and reinforcement learning problems. J Machine Learn Res 2006; 7: 1079.
- Bubeck S., Munos R. and Stoltz G.: Pure exploration in finitely-armed and continuous-armed bandits. Theoret Comput Sci 2011; 412: 1832. · DOI · Paper page
- Hardwick J. and Stout Q.F.: Bandit strategies for ethical sequential allocation. Comp Sci Stat 1991; 23: 421.
- Armitage P.: The search for optimality in clinical trials. Int Statist Rev/Rev Int Statist 1985; : 15. · DOI
- Villar S.S., Bowden J. and Wason J.: Multi-armed bandit models for the optimal design of clinical trials: benefits and challenges. Stat Sci 2015; 30: 199. · DOI · Paper page
- Villar S.S.: Bandit strategies evaluated in the context of clinical trials in rare life-threatening diseases. Probab Eng Inf Sci 2018; 32: 229. · DOI
- Chapelle O Li L. An empirical evaluation of Thompson sampling. In: Advances in neural information processing systems; 2011. p. 2249–57).
- Thall P.F. and Wathen J.K.: Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007; 43: 859. · DOI · Paper page
- 10.1038/nrd1927 · DOI · Paper page
- Varatharajah Y Berry B Koyejo S Iyer R. A Contextual-bandit-based Approach for Informed Decision-making in Clinical Trials; 2018. arXiv preprint arXiv:1809.00258. · arXiv
- Durand A Achilleos C Iacovides D Strati K Mitsis GD Pineau J. Contextual bandits for adapting treatment in a mouse model of de novo carcinogenesis. In: Machine learning for healthcare conference; 2018 p. 67–82.
- 10.1093/bib/bbr005 · DOI · Paper page
- Bisgin H., Liu Z., Kelly R., Fang H., Xu X. and Tong W.: Investigating drug repositioning opportunities in FDA drug labels through topic modeling. In BMC bioinformatics. BioMed Central 2012; 13: S6.
- Tari L.B. and Patel J.H.: Systematic drug repurposing through text mining. In: Biomedical Literature Mining. New York, NY: Humana Press 2014: 253. · DOI
- Alaimo S., Giugno R. and Pulvirenti A.: Recommendation techniques for drug–Target interaction prediction and drug repositioning. In: Data mining techniques for the life sciences. New York, NY: Humana Press 2016: 441. · DOI
- 10.1093/bib/bbr021 · DOI · Paper page
- Zhang W., Yue X., Huang F., Liu R., Chen Y. and Ruan C.: Predicting drug-disease associations and their therapeutic function based on the drug-disease association bipartite network. Methods 2018; 145: 51. · DOI
- Gilvary C., Madhukar N., Elkhader J. and Elemento O.: The missing pieces of artificial intelligence in medicine. Trends Pharmacol Sci 2019; . · DOI
- 10.1016/j.inffus.2018.09.012 · DOI · Paper page
- Carvalho-Silva D., Pierleoni A., Pignatelli M., Ong C., Fumis L., Karamanis N. et al: Open targets platform: new developments and updates two years on. Nucleic Acids Res 2018; 47: D1056. · DOI · Paper page
- Davis A.P., Grondin C.J., Johnson R.J., Sciaky D., McMorran R., Wiegers J. et al: The comparative toxicogenomics database: update 2019. Nucleic Acids Res 2018; 47: D948. · DOI · Paper page
- Piñero J., Bravo À., Gutiérrez-Sacristán A., Centeno E., Deu-Pons J. and García J.: DisGeNET, a centralized repository of the genetic basis of human diseases. F1000Research 2017; 6.
- 10.1093/dnares/dsl005 · DOI
- Boué S., Talikka M., Westra J.W., Hayes W., Di Fabio A., Park J. et al: Causal biological network database: a comprehensive platform of causal biological network models focused on the pulmonary and vascular systems. Database 2015; 2015. · DOI
- 10.1126/science.1132939 · DOI · Paper page
- Li Y.H., Yu C.Y., Li X.X., Zhang P., Tang J., Yang Q. et al: Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res 2017; 46: D1121. · DOI · Paper page
- Von Eichborn J., Murgueitio M.S., Dunkel M., Koerner S., Bourne P.E. and Preissner R.: PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res 2010; 39: D1060. · DOI · Paper page
- 10.1038/sdata.2017.29 · DOI · Paper page
- 10.1093/nar/gky092 · DOI · Paper page
- Gaulton A., Hersey A., Nowotka M., Bento A.P., Chambers J., Mendez D. et al: The ChEMBL database in 2017. Nucleic Acids Res 2016; 45: D945. · DOI · Paper page
- Koscielny S.: Why most gene expression signatures of tumors have not been useful in the clinic. Sci Transl Med 2010; 2. · DOI
- Guyon I. and Elisseeff A.: An introduction to variable and feature selection. J Machine Learn Res 2003; 3: 1157.
- Zeng X., Zhu S., Liu X., Zhou Y., Nussinov R. and Cheng F.: deepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics 2019; .
- Delahaye-Duriez A., Srivastava P., Shkura K., Langley S.R., Laaniste L., Moreno-Moral A. et al: Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery. Genome Biol 2016; 17: 245. · DOI
- Ahmed SS Roy S Kalita JK. Assessing the effectiveness of causality inference methods for gene regulatory networks. IEEE/ACM transactions on computational biology and bioinformatics; 2018.
- Young WC Yeung KY Raftery AE. A posterior probability approach for gene regulatory network inference in genetic perturbation data; 2016. arXiv preprint arXiv:1603.04835. · DOI
- Tardif J.C., Rhainds D., Brodeur M., Feroz Zada Y., Fouodjio R., Provost S. et al: Genotype-dependent effects of dalcetrapib on cholesterol efflux and inflammation: concordance with clinical outcomes. Circulation: Cardiovascular. Genetics 2016; 9: 340.
- Burki T.: Pharma blockchains AI for drug development. Lancet 2019; 393: 2382. · doi:10.1016/s0140-6736(19)31401-1
- Brown A.S., Kong S.W., Kohane I.S. and Patel C.J.: ksRepo: a generalized platform for computational drug repositioning. BMC Bioinf 2016; 17: 78. · DOI
- Pallmann P., Bedding A.W., Choodari-Oskooei B., Dimairo M., Flight L., Hampson L.V. et al: Adaptive designs in clinical trials: why use them, and how to run and report them. BMC medicine 2018; 16: 29. · DOI · Paper page
Cited by
Addressing bias in big data and AI for health care: A call for open science
Norori, N., Hu, Q., Aellen, F. M., Faraci, F. D., & Tzovara, A. (2021) · Patterns · doi:10.1016/j.patter.2021.100347 · Cited by 903
Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., Ramirez, B. I., Sánchez-Guirales, S. A., Simon, J. A., Tomietto, G., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101328 · Cited by 488
Machine Learning Methods in Drug Discovery
Patel, L., Shukla, T., Huang, X., Ussery, D. W., & Wang, S. (2020) · Molecules · doi:10.3390/molecules25225277 · Cited by 460
Utilizing graph machine learning within drug discovery and development
Gaudelet, T., Day, B., Jamasb, A. R., Soman, J., Regep, C., Liu, G., Hayter, J. B. R., Vickers, R., Roberts, C., Tang, J., et al. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab159 · Cited by 313
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2273839 · Cited by 235
“Consequently, interest in the application of ML to drug discovery and development has grown [33,34].”
BackgroundThe use of machine learning in rare diseases: a scoping review
Schaefer, J., Lehne, M., Schepers, J., Prasser, F., & Thun, S. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01424-6 · Cited by 213
“However, machine learning can also play an important role in improving the treatment of rare diseases, and future studies could focus more on this aspect, for example by using machine learning to accelerate drug development [33].”
BackgroundHamamoto, R., Suvarna, K., Yamada, M., Kobayashi, K., Shinkai, N., Miyake, M., Takahashi, M., Jinnai, S., Shimoyama, R., Sakai, A., et al. (2020) · Cancers · doi:10.3390/cancers12123532 · Cited by 207
Utility of Artificial Intelligence Amidst the COVID 19 Pandemic: A Review
Bansal, A., Padappayil, R. P., Garg, C., Singal, A., Gupta, M., & Klein, A. (2020) · Journal of Medical Systems · doi:10.1007/s10916-020-01617-3 · Cited by 87
Hou, T., Bian, Y., McGuire, T., & Xie, X.-Q. (2021) · Biomolecules · doi:10.3390/biom11060870 · Cited by 30
Metadata
- Authors
- Réda, C., Kaufmann, E., & Delahaye-Duriez, A.
- Venue
- Computational and Structural Biotechnology Journal
- Published
- 2020
- Volume
- 18
- Pages
- 241-252
- ISSN
- 2001-0370 (ISSN-L)
- OpenAlex
- W2997578645
- Cited by
- 228
- References
- 21
- FWCI
- 17.68
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Centre National de la Recherche Scientifique
- Agence Nationale de la Recherche
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.